ContractConvertible Loan Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 18th, 2022 Company IndustryPursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
SERVICE AGREEMENTService Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 18th, 2022 Company IndustryThis Service Agreement (“Agreement”) is made of and entered into on 08th September 2021 between CytoMed Therapeutics (Malaysia) Sdn. Bhd. (“Company”) and Choo Chee Kong (“Service Provider”).
ContractPut Option Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 18th, 2022 Company IndustryPursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
ContractLicense Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 18th, 2022 Company IndustryPursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
ContractShareholders Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 18th, 2022 Company IndustryPursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
ContractLicence Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 18th, 2022 Company IndustryPursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
ContractLicense Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 18th, 2022 Company IndustryPursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
ContractSupplemental Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 18th, 2022 Company IndustryPursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
ContractSubscription Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 18th, 2022 Company IndustryPursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
ADDENDUM TO LICENCE AGREEMENTLicense Agreement • November 18th, 2022 • CytoMed Therapeutics Pte. Ltd. • Pharmaceutical preparations
Contract Type FiledNovember 18th, 2022 Company IndustryACCELERATE TECHNOLOGIES PTE LTD, f.k.a.EXPLOIT TECHNOLOGIES PTE LTD (Co. Reg. No. 1995053187D), a company incorporated in Singapore and having its place of business at 1 Fusionopolis Way, #19-00 Connexis North, Singapore 138632 (hereinafter referred to as “A*ccelerate”) ; and